| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 30, 2005
Accepted on April 18, 2006
Clinical Research Center of North Texas, Denton, TX; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Oregon Osteoporosis Center, Portland, OR; University of Maryland School of Medicine, Baltimore, MD; Massachusetts General Hospital, Endocrine Unit, Boston, MA; Arthritis Associates, Palm Harbor, FL; Foundation for Osteoporosis Research and Education, Oakland, CA; Merck & Co., Inc., West Point, PA
* To whom correspondence should be addressed. E-mail: sbonnick{at}msn.com.
Objective: A 1-year extension of the FOSAMAX® ACTONEL® Comparison Trial (FACT) was completed to compare changes in bone mineral density (BMD), bone turnover, and upper gastrointestinal tolerability over 2 yr of treatment.
Design: Randomized, double-blind extension conducted at 72 US sites.
Patients and Methods: Of the 1053 women who completed Year 1, 833 postmenopausal women with low BMD entered the extension, continuing their same treatment allocation (once-weekly (OW) alendronate 70 mg or OW risedronate 35 mg). Changes in BMD at the hip trochanter, total hip, femoral neck, and lumbar spine and in markers of bone turnover were compared at 24 months. Tolerability was assessed by adverse experience reporting.
Results: Alendronate produced greater increases from baseline in BMD at 24 months than did risedronate at the trochanter (ALN, 4.6%; RIS, 2.5%, P < 0.001), as well as at all other BMD sites. Significantly more alendronate than risedronate patients had measured BMD increases of 
0% and 3% at all BMD sites (P < 0.001), and fewer alendronate patients had measured decreases of 3% at all BMD sites. Significantly greater reductions in all biochemical markers of bone turnover occurred with alendronate compared with risedronate. No differences were seen in occurrence or discontinuations due to upper gastrointestinal adverse experiences.
Conclusions: Patients receiving OW alendronate 70 mg had greater gains in BMD, were more likely to maintain or gain BMD, and had greater reductions in bone turnover markers than patients receiving OW risedronate 35 mg after 24 months, with no differences in upper gastrointestinal tolerability.
This article has been cited by other articles:
 |
|
 |
|
  S.-A. M. Burnett-Bowie, K. Saag, A. Sebba, A. E. de Papp, E. Chen, E. Rosenberg, and S. L. Greenspan Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1097 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Hershman, D. J. McMahon, K. D. Crew, S. Cremers, D. Irani, G. Cucchiara, L. Brafman, and E. Shane Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer J. Clin. Oncol., October 10, 2008; 26(29): 4739 - 4745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Qaseem, V. Snow, P. Shekelle, R. Hopkins Jr., M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, September 16, 2008; 149(6): 404 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Cadarette, J. N. Katz, M. A. Brookhart, T. Sturmer, M. R. Stedman, and D. H. Solomon Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture Ann Intern Med, May 6, 2008; 148(9): 637 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G Clay, L. E Voss, C. Williams, and E. C Daume Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons Ann. Pharmacother., May 1, 2008; 42(5): 670 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Black, P. D. Delmas, R. Eastell, I. R. Reid, S. Boonen, J. A. Cauley, F. Cosman, P. Lakatos, P. C. Leung, Z. Man, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis N. Engl. J. Med., May 3, 2007; 356(18): 1809 - 1822. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
